OSKA Pulse added to BARMER’s ENDOPOWER program for endometriosis care

OSKA Pulse, a wearable PEMF device, has been added to BARMER’s ENDOPOWER program in Germany, giving women with endometriosis and adenomyosis a drug-free option within insurer-backed care. The move positions wearable technology as part of a structured pathway for chronic pelvic pain, not a replacement for medical treatment.

Why it matters: - Endometriosis affects about one in 10 women of reproductive age, or an estimated 190 million people worldwide. - Adenomyosis creates a similar burden and often requires long-term symptom management. - BARMER’s ENDOPOWER program is one of the first insurer programs focused specifically on these conditions. - The program adds a drug-free, non-invasive option to care that often relies on hormonal medication, pain relief and repeated surgery.

What happened: - OSKA Pulse has been included in ENDOPOWER, a structured care program run by BARMER, one of Germany’s largest statutory health insurers. - The addition gives eligible members access to OSKA Pulse as part of care for endometriosis and adenomyosis in Germany. - BARMER State Director Joao Rodrigues said Endopower is “an alternative to burdensome medications or recurring surgeries.” - OSKA describes the device as a wearable, at-home option that members can use alongside existing care.

The details: - OSKA Pulse uses pulsed electromagnetic field technology, or PEMF, to deliver low-level electromagnetic signals intended to support the body’s natural recovery processes and help manage pain. - The device is compact, wearable and designed for repeated daily use at home. - ENDOPOWER combines specialist input, online advisory services and supportive technologies for eligible members. - OSKA Pulse was added after collaboration with German specialist partners, including Electro-Zeutika and clinical specialists involved in the program. - For more information about OSKA Pulse, visit the company’s announcement. - OSKA Pulse is already used worldwide for a range of chronic pain conditions.

Between the lines: - The inclusion signals growing insurer interest in drug-free, technology-led approaches to chronic pain. - The program also reflects a broader push to offer women more support between clinical appointments, not just during episodic care. - OSKA says the ENDOPOWER partnership gives the company a chance to show how wearable technology can complement established medical treatment in a real-world insured population. - The move also comes amid rising attention on women’s health and persistent gaps in research, funding and treatment options.

What’s next: - OSKA said it will keep working with partners, clinicians and health insurers internationally to expand access to drug-free pain management for women with endometriosis and adenomyosis. - The company sees ENDOPOWER as a model other insurers and health systems may consider. - OSKA wants to demonstrate that wearable technology can play a role in everyday pain management while being backed by a recognized insurer and used at home.

The bottom line: - BARMER’s ENDOPOWER program now gives women with endometriosis and adenomyosis a structured, insurer-backed path to try a wearable, drug-free pain management option alongside standard care.